Scholar Rock | Discovery and Development of Innovative Medicines
Sep 30, 2024 · At Scholar Rock, we are on a mission to discover, develop, and deliver therapies to improve people’s lives. We are a biopharmaceutical company combining bold science with a deep commitment to make a meaningful difference …
Our Pipeline - Scholar Rock
Scholar Rock is turning scientific discoveries into a pipeline of investigational therapies aimed at diseases where growth factors play a central role. Our therapeutic approach selectively targets the latent forms of growth factors, which can get to the underlying biology of …
Our Company - Scholar Rock
We are Scholar Rock. A biopharmaceutical company dedicated to discovering, developing, and delivering therapies that create new possibilities for patients. Learn More About Our Pipeline
Careers - Scholar Rock
Our science isn’t the only area where we cultivate potential. Scholar Rock offers unique opportunities to apply your expertise and insights within a focused, commercial-ready environment, so you can continue growing professionally in both knowledge and skills.
Spinal Muscular Atrophy - Scholar Rock
Scholar Rock is the first company to show clinical proof-of-concept for an investigational muscle-targeted therapy in SMA. Despite significant advances in SMA treatments, progressive muscle weakness continues to be a hallmark of the disease.
Management Team - Scholar Rock
We are Scholar Rock. A biopharmaceutical company dedicated to discovering, developing, and delivering therapies that create new possibilities for patients. Learn More About Our Pipeline
Board of Directors - Scholar Rock
We are Scholar Rock. A biopharmaceutical company dedicated to discovering, developing, and delivering therapies that create new possibilities for patients. Learn More About Our Pipeline
Press Releases - Scholar Rock, Inc.
Jan 29, 2025 · Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Read More
Scholar Rock Receives Fast Track Designation from the U.S. FDA …
May 24, 2021 · Scholar Rock’s newly elucidated understanding of the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level.
Scholar Rock Submits Biologics License Application (BLA) to the …
Jan 29, 2025 · Scholar Rock remains on track to submit the apitegromab Marketing Authorisation Application (MAA) to the European Medicines Agency in 1Q 2025, with PRIME and Orphan Medicinal Product Designations
- Some results have been removed